I believe that what you're saying is true, but onl

I believe that what you're saying is true, but only partially so. I believe that revenue from psoriasis cream sales will dramatically increase the share price, and funding for a series of new clinical trials will come from both sales revenue as well as funding based on substantially higher share prices.

In the 10-Q I noted that they mentioned expanding the size of the Phase 1 Safety trials to look at certain markers. In that the trial was at least originally intended to enroll only healthy patients, I'm wondering if the marker's they're looking at represent patients with psoriasis who'll be added at the end of the trial, when safety of healthy patients has already been insured. If others see it differently, please help me by explaining the markers they could look at in healthy patients.

I'm certainly not a technical matters expert, but I believe the company could end the confusion by conducting a webcast and answering questions, such as, how do they explain the latest update of the website indicating the cream and sublingual pills are available for sales. I suspect they're not yet ready to answer all these questions, but rather they're giving us a hint of coming attractions.

I think the next major announcement from the company could involve how U.S. sales will be handled. I'm uncertain if a single company can do it, or it will be done State by State, with in some cases one company being able to service more than a single State. Even an announcement that only applied to California would be huge, as it's a market that's as big as many smaller countries combined.

Gary